Kornimate/medical-research-clean huggingface dataset:
effects of eldoa and post-facilitation stretching technique on pain and disability in patients with text neck syndrome

Conditions: Neck Pain

Summary: in this modern era, text neck is a new term used to describe neck pain and associated damage caused by continuous flexed posture due to excessive use of smartphones for a long time. the term text neck was first introduced by dr. dean l. fishman, who is us based chiropractor. text neck can also be described as overuse syndrome caused by repetitive stress on neck due to prolonged flexion. there is coordinated work between cervical spine and surrounding structure such as muscles, ligament, nerves and bones. in addition, any nerve compression at cervical spine leads to radiating pain in neck, shoulder and arm. previous literature reported use of cell phone is very common in population of 18 to 44 years of age. seventy nine percent (79%) population have smartphone with them all the time. technology has become essential part of modern lifestyle. sustained flexed posture forces the head to exert weight on neck of varying degrees. weight of neutral head is 10 to 12 pounds and increases 6 times 1 inch forward movement of head. children are at higher risk because of their large head size. this study will be a randomized clinical trial with objective to reduce neck pain and disability in patients with text neck syndrome. two groups will be designed, in one group eldoa (n=20) and in other group post facilitation technique (n=20) will be applied. patients will be recruited into two groups by consecutive sampling by non-replacement lottery method with equal no. of chits. patients will be assessed by numeric pain rating scale (nprs), neck disability index (ndi), smartphone addiction scale before and after treatment. both groups will receive heating pad as common treatment first after that group a will be treated with eldoa and group b will be treated with post-facilitation. session of 6 weeks with 3 days per week will be conducted. after that post treatment assessment will be done.


Eligibility criteria:
inclusion criteria: * • neck pain without unilateral ue symptoms * age 18-35 years * subjects using phone since past 1 year * neck disability index (ndi) score \>10 points * participants able to understand and fill the questionnaire in english exclusion criteria: * • subjects having any congenital cervical condition * subjects having traumatic cervical condition such as whiplash injury within the past 6 weeks * history of spinal tumors, spinal infection, cervical spine fracture, or previous neck surgery * subjects with cervical radiculopathy

Keywords: text neck syndrome
creative arts diabetes initiative for youth/young adults transitioning to adult care

Conditions: Coping Behavior; Emotional Distress; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2

Summary: the creative arts diabetes initiative will offer facilitated art therapy with a group/peer-support environment to two groups of youth/young adults, one with type 1 diabetes, and one with type 2 diabetes. this environment intends to "meet youth where they are", promote universality, hope and self-understanding, has the potential to be therapeutic and allows youth to express and learn about themselves and each other while developing healthy coping skills and address their fears and concerns.

the creative arts diabetes initiative will offer facilitated art therapy with a group/peer-support environment to two groups of youth/young adults, one with type 1 diabetes, and one with type 2 diabetes. this environment intends to "meet youth where they are", promote universality, hope and self-understanding, has the potential to be therapeutic and allows youth to express and learn about themselves and each other while developing healthy coping skills and address their fears and concerns. as much of diabetes management is about meeting physical health goals - it is the vision of this study that offering additional support in the form of art therapy will have positive effects for bringing awareness and avenues for self-care to the other often neglected dimensions of patients' mental, emotional and spiritual health as part of a more holistic health process. engaging in art therapy has the potential to decrease diabetes related distress by giving youth a means and opportunity to identify, understand and express their feelings about having diabetes. improved self-awareness and self-reflectiveness can help youth integrate their feelings and learn how this can motivate, influence and impact their behaviors and life choices. youth will have the opportunity for engaging in peer support, and to build relationships that are meaningful, thus increasing their sense of belonging and positively affect their level of self-confidence, purpose and wellbeing.

Eligibility criteria:
inclusion criteria: * diagnosed with either type 1 or type 2 diabetes, live within weekly travel distance to winnipeg, manitoba, receive their pediatric care at the diabetes education resource for children and adolescents, or who are members of the maestro project exclusion criteria: * those who cannot give informed consent or who are not able to attend regular sessions due to travel distance

Keywords: type 1 diabetes type 2 diabetes children adolescents young adults youth transition art therapy behavioral therapy
improving sleep with a digital cognitive behavioral therapy for insomnia application

Conditions: Insomnia

Summary: insomnia is an important public health problem and the most common sleep disorder in the general population. up to 20% of adults in the united states suffer from insomnia disorder, and it has been associated with increased morbidity, mortality, and healthcare costs. cognitive behavioral therapy for insomnia (cbt-i) is the initial recommended treatment approach for insomnia. combined therapy with cbt-i and medication has shown no advantage over cbt-i alone. cbt-i is not always accessible to patients, however, due to cost and availability of trained healthcare professionals. web-based cbt-i is an inexpensive and effective self-management tool for treatment of insomnia. this pilot study would test the efficacy of a new digital cbt-i application called stellar sleep, a cost effective and user-friendly version of wcbt-i, in patients with insomnia. this is the first digital cbt-i app that allows automatic entry of sleep diary data from wearable devices that track sleep (such as the mi band 5 or a fitbit, for instance). testing the efficacy of this application will provide the preliminary data necessary for larger trials to further validate the application and determine its role for future patients. use of this application can help bridge the gap in providing care to insomnia patients with transportation and cost barriers and to accommodate the long wait times for traditional in-person cbt-i. it will also be the first web-based cbt-i application that can directly upload data from a wearable device.


Eligibility criteria:
inclusion criteria: * 18 years or older * daily access to a computer or smartphone with reliable internet connection exclusion criteria: * currently pregnant or planning to become pregnant in the next year * visual impairment that prevents use of a computer * serious health conditions that will prevent taking part in the study over the next 3 - 6 months, such as severe medical or psychiatric disease, such as treatments for cancer or congestive heart failure, or a condition that may require hospitalization or surgery * self-reported history of drowsy driving or fallen asleep while driving * night shift worker * prior exposure to cognitive behavioral therapy for insomnia (cbt-i) treatment * insomnia severity index score \< 14
nets formation in patients with recurrent pyogenic infections (nets)

Conditions: Pyogenic Infections

Summary: we aim to study if pathological nets formation could be the underlying pathology among patients with recurrent infections and a normal screening of the immune system.

our laboratory at meir medical center, kfar saba, is the country's main center for neutrophil function, and serves about 80% of israel's population. patients are referred subsequent to recurrent, persistent, or unusual infections and after completing preliminary screening of the immune system and ruling out a humoral, cellular or complement immune deficiency. initial workup includes chemotaxis, superoxide production (sop), and bactericidal activity (ba). based on test findings, further evaluation for a qualitative phagocytic disorder is conducted. overall, impairment of phagocytic activity is found in about 33% (impaired chemotaxis in 16%, sop in 6%, and ba in 24%). in the other 67%, no impairment of the immune function is found that can explain their tendency for recurrent pyogenic infections. in 2004 a novel function of the neutrophil was identified: formation of neutrophil extracellular traps (nets). apparently, neutrophils are able to extrude part of their cellular contents in the form of dna, histones and proteases, to form extra cellular nets that trap and kill bacterial pathogens without the need for phagocytosis. we aim to study if pathological nets formation could be the underlying pathology among these patients with recurrent infections and a normal screening of the immune system.

Eligibility criteria:
inclusion criteria: * patients with recurrent, persistent, or unusual infections * referred for neutrophil functions exclusion criteria: * none

Keywords: nets infections neutrophil function
neoadjuvant chemotherapy with nab-paclitaxel plus cisplatin for stage ⅱ-ⅲ esophageal cancer patients

Conditions: Esophageal Squamous Cell Carcinoma

Summary: the purpose of this study is to evaluate the efficacy and safety of neoadjuvant chemotherapy with nab-paclitaxel plus cisplatin for stage ⅱ-ⅲ esophageal squamous cell carcinoma patients.

a surgical resection is currently the preferred treatment for esophageal cancer if the tumor is considered to be resectable without evidence of distant metastases.a higher percentage of radical resection is reported in studies using neoadjuvant chemotherapy followed by surgery versus surgery alone.the neoadjuvant chemotherapy may improve overall survival. neoadjuvant chemotherapy with administrations of paclitaxel combined with cisplatin or carboplatin has shown effectively.nanoparticle albumin-bound (nab)-paclitaxel has better efficacy and practically eliminates the risk of hypersensitivity reactions associated with solvent-based paclitaxel.we try to evaluate the efficacy and safety of neoadjuvant chemotherapy with nab-paclitaxel plus cisplatin for stage ⅱ-ⅲ esophageal squamous cell carcinoma patients.

Eligibility criteria:
inclusion criteria: * histologic diagnosis of squamous cell carcinoma of esophagus. preoperative stage ⅱ-ⅲ by endoscopic ultrasound, ct of the chest and abdomen,and esophagogram. * age ranges from 18 to 70 years. * patients must not have received any prior anticancer therapy. * performance status of 0 to 1 * estimated life expectancy of at least 6 months. * tumor can be measured according to recist criteria * signed informed consent document on file. * females with childbearing potential must have a negative serum pregnancy * adequate organ function including the following: bone marrow: absolute neutrophil count (anc) greater than or equal 1.5×109/l platelets greater than or equal 80×109/l haemoglobin greater than or equal 80g/l hepatic: total bilirubin less than or equal to 1.5 times upper limit of normal (uln), alanine transaminase (alt) and aspartate transaminase (ast) less than or equal to 2.5 times uln renal: calculated creatinine clearance rate≥60ml/min. test within 7 days prior to study enrollment. exclusion criteria: * carcinoma at the upper part of esophagus * histologic diagnosis of adenocarcinoma of esophagus. * prior treatment for esophageal cancer. * active infection. * pregnant or breast feeding. * history of significant neurological or mental disorder, including seizures or dementia. * prior invasive malignancy in 5 years (except for carcinoma in situ).

Keywords: esophageal squamous cell carcinoma neoadjuvant chemotherapy albumin-bound paclitaxel cisplatin
the efficacy and safety of colchicine combined with conventional therapy in multiple myeloma patients

Conditions: Multiple Myeloma

Summary: to evaluate the efficacy and safety of investigational drug colchicine combined with conventional lenalidomide based therapy in multiple myeloma subjects who had received first-line therapy (including chimeric antigen receptor t-cell immunotherapy (cart) treatment), and to evaluate the quality of life of the patients.

this study is expected to be carried out from march 2022 to december 2024. about 30 patients with multiple myeloma who have received at least first-line of treatment (including chimeric antigen receptor t-cell immunotherapy (cart) treatment) will be randomly assigned to the experimental group or the control group at 2:1. by comparing the relevant data such as efficacy evaluation and safety evaluation after treatment, the principal investigator will write and publish the paper.

Eligibility criteria:
inclusion criteria: clinical diagnosis of multiple myeloma have received at least one-line treatment must be able to swallow tablets exclusion criteria: resistance to or intolerance to therapeutic agents such as bortezomib or lenalidomide allergy to the experimental drug or its ingredients has invaded the central nervous system severe cardiovascular, liver and kidney failure, severe chronic obstructive pulmonary disease (copd), and moderate to severe asthma active hepatitis b or c infection hiv seropositivity is participating in other clinical trials or has participated in other clinical trials within the past two weeks other factors that the researchers determined were not suitable for the trial

Keywords: multiple myeloma colchicine
prognostic factors in nop-lbbb after tavi

Conditions: Transcatheter Aortic Valve Replacement

Summary: the goal of this observational study is to find prognostic factors in patients with a new-onset persistent left bundle branch block (nop-lbbb) after transcatheter aortic valve implantation (tavi). the main question it aims to answer is: are there any factors influencing heart failure or death risk during the year following tavi in patients with nop-lbbb ? participants will have data collection about tavi procedure and clinical evolution during a one-year follow-up.


Eligibility criteria:
inclusion criteria: * new-onset persistent left bundle branch block after transcatheter aortic valve implantation exclusion criteria: * pre-existing left bundle branch block * pre-existing right bundle branch block * pre-existing permanent pacemaker * immediate procedural mortality (death ≤72 h post-procedure)

Keywords: transcatheter aortic valve implantation, aortic stenosis, permanent pacemaker, left bundle branch block, heart failure, cardiac dyssynchrony
optical coherence tomography of airway and pleural disorders

Conditions: Disorder of Pleura and Pleural Cavity

Summary: the researcher can use optical coherence tomography a near-infrared diode to emit light that can produce images of the specimen under investigation and provide information about tissue abnormalities without causing damage.

the researcher can use optical coherence tomography endoscopic imaging to improve diagnosis and treatment of airway and pleural malignancy. in the events of burn injury and smoke inhalation injury, the optical coherence tomography can determine the change of the airway tissues and severity of airway injury. during endoscopic procedure the lesions will be biopsied and prepared by standard histologic methods. the optical coherence tomography endoscopic imaging can measured histologic of the tissue samples and compared to standard histologic examination. the optical coherence tomography endoscopic imaging can measured the epithelial thickness and compared to visual inspection of the mucosa on bronchoscopy.

Eligibility criteria:
inclusion criteria: * adult 18 or older, male or female. * plans for bronchoscopic with possible biopsy procedures. exclusion criteria: * age less than 18 years of age * not plan for bronchoscopic with possible biopsy procedures. * pregnant or breastfeeding.
detection of bone marrow metastases with magnetic resonance imaging

Conditions: Bone Marrow Metastases; Magnetic Resonance Imaging

Summary: the goal of this clinical trial is to study the value and feasibility of magnetic resonance imaging in detection of bone marrow metastases

the patient was diagnosed as bone metastasis by pathology. ct showed no bone marrow biopsy site metastasis (anterior iliac spine or posterior iliac spine). after functional magnetic resonance examination, bone marrow biopsy was performed. functional magnetic resonance imaging includes conventional se sequence, t2w spair, e-thrive,dwi,ivim. with bone marrow biopsy as the gold standard, the sensitivity, specificity and coincidence rate of functional mri in the diagnosis of bone marrow metastasis were evaluated.

Eligibility criteria:
inclusion criteria: 1. patients with malignant tumors (solid tumors or hematological malignancies) were definitely diagnosed by pathology or cytology. 2. patients with bone metastases confirmed by more than two imaging examinations. 3. age 18-75. 4. ecog score: 0-2. 5. the expected survival time is more than 3 months. 6. sign the informed consent. exclusion criteria: 1. imaging findings suggest that bone metastases are present at the bone marrow puncture site. 2. the patient refused bone marrow puncture. 3. puncture site with infection. 4. severe coagulation dysfunction. 5. there are implanted instruments in the body, so magnetic resonance imaging can not be performed.
vitamin d supplementation as a neoadjuvant for photodynamic therapy of actinic keratoses

Conditions: Actinic Keratosis

Summary: this study is open to individuals with actinic keratoses (skin lesions that have the potential to turn into skin cancer), who are receiving photodynamic therapy (pdt) as part of their clinical care. the purpose of this study is to test and demonstrate that vitamin d pre-treatment can enhance pdt efficacy in the treatment of actinic keratoses. participants will be asked to take vitamin d supplements prior to their standard of care pdt treatment. participation in the research will last about 3-4 months.

the primary objective of this study is to determine whether acute supplementation (neoadjuvant vitamin d3), adjusted according to baseline vitamin d status, can improve the clinical pdt response relative to participants receiving pdt alone the secondary objective of this study is to determine whether gene polymorphisms in vdr and cyp27b1 are predictive for the degree of responsiveness to vitamin d as a neoadjuvant for pdt. this study is a non-randomized interventional trial, in which the study group will be compared to a baseline cohort of patients from a previous study who received the same regimen of pdt, but without any vit d. it is anticipated that 30 participants will be involved in this study.

Eligibility criteria:
inclusion criteria: * actinic keratoses in sufficient numbers (\>10) to warrant pdt therapy in the clinic * able to understand and willing to sign a written informed consent document * female subjects must not become pregnant during the study: * the effects of 5-aminolevulinic acid (levulantm) on the human fetus are unknown. for this reason, women of child-bearing potential must agree to use contraception (double barrier method of birth control or abstinence) prior to study entry, and throughout study participation. should a woman become pregnant or suspect that she is pregnant while she is participating in this study, she should inform the treating physician immediately. exclusion criteria: * pregnant or nursing. * at risk for hypercalcemia (renal disease, sarcoidosis, etc.) * using topical retinoids, since these can exacerbate the post-pdt erythema reaction. * using any topical treatment on their aks; must stop at least one month prior. * currently undergoing treatment for other cancers with medical or radiation therapy. * patients with a known hypersensitivity to 5-aminolevulinic acid or any component of the study material. * patients with history of a photosensitivity disease, such as porphyria cutanea tarda. * currently participating in another clinical trial.
contingency management in hiv care for both stimulant use & art adherence

Conditions: Stimulant Use (Diagnosis); Hiv

Summary: methamphetamine use and associated sequelae have been rising, and represent a major barrier to successful control of the hiv epidemic. methamphetamine use is associated with poor adherence to antiretroviral therapy for hiv, and the investigators propose a trial of contingency management (providing incentives for behavioral change) targeting both reduced methamphetamine use and improved adherence to hiv medications. the investigators will utilize a real-time, point-of-care urine assay for both outcomes, aiming to evaluate feasibility, acceptability and preliminary effectiveness of hiv care-based contingency management. hair levels will also be studied as a quantitative outcome for reduction in methamphetamine use.

methamphetamine (ma) use is increasing in the united states, along with a sharp rise in overdose deaths. ma use is particularly prevalent among people with hiv (pwh), which can contribute to non-adherence to antiretroviral therapy (art) and progression to aids. contingency management (cm) is an evidence-based intervention that has repeatedly demonstrated efficacy in stimulant use disorder treatment and has also proved efficacious in improving art adherence for those in care. since uptake of cm outside of formal drug treatment programs has been limited, incorporating cm into hiv primary care is an important opportunity to expand access to treatment for ma use disorder while also supporting art adherence. this study addresses two barriers that have each limited outward expansion of cm into hiv primary care: 1) feasibility challenges for cm in clinical practice settings; as cm is traditionally delivered 2-3x weekly, this study explores a de-intensified cm schedule (e.g., once weekly visits) in hiv primary care; and 2) cm for art adherence has been previously limited by the inaccuracy of indirect or non-timely measures of adherence. the study utilizes a novel point-of-care urine tenofovir assay to perform poc testing on the same urine specimen for both art use and ma non-use, enabling a truly paired cm intervention that addresses the following aims: 1) a pilot rct evaluating feasibility of de-intensified (once weekly) combined contingency management for reducing ma use and increasing art adherence in hiv primary care, compared to conventional twice weekly cm; 2) in-depth interviews following rct completion to qualitatively explore the acceptability of this intervention to participants and their primary care providers; and 3) given incomplete ability to detect cumulative ma use with only once weekly urine testing, the investigators will study the correlation between monthly ma hair levels with monthly timeline followback interviews to validate use of hair ma levels to be able to quantitatively detect reduced use (in addition to abstinence) as a future study outcome.

Eligibility criteria:
inclusion criteria: * stimulant use disorder * living with hiv or risk for hiv * suboptimal art adherence (treatment or prevention) exclusion criteria: * unable to provide urine testing weekly